Mr. Scott Cormack has more than two decades of experience in the biotechnology industry in executive management and venture capital. Scott has been President and CEO of OncoGenex since August 2008, when OncoGenex Technologies Inc. completed a reverse takeover of Sonus Pharmaceuticals, Inc. to become OncoGenex Pharmaceuticals, Inc. Scott has led OncoGenex through significant corporate milestones, including private financings, leading the company from pre-clinical studies to completion of multiple Phase 2 clinical trials, initiation of Phase 3 trials and development of a robust pipeline. Scott was a co-founder of OncoGenex Technologies Inc., now a wholly owned subsidiary, where he served as President and a member of the Board of Directors since May 2000 and as Chief Executive Officer since February 2002. From 1998 to 2001, Scott served as Vice President of Milestone Medica Corporation, a seed venture capital firm investing in life sciences opportunities and joint venture between RBC Technology Ventures Inc. and Research Corporation Technologies. While at Milestone Medica, Scott served as interim President, Chief Executive Officer and Chairman of the Board of Directors of Salpep Biotechnology Inc., an asthma and inflammation biotechnology company, from 2000 to 2001. From 1995 to 1998, Scott served as Chief Operating Officer of NeuroSpheres Ltd, a neural stem cell biotechnology company. He was President and founder of For Tomorrow, a sole proprietorship engaged in business consulting, from 1991 to 1999. From 1986 to 1988, Scott served as Territory Manager of Vetrepharm Inc. (now Bioniche Life Sciences, Inc.), a biopharmaceutical company developing products for human and animal health markets, and from 1988 to 1991 he served as its Technology Manager, Immunomodulators. Scott holds a B.S. degree from the University of Alberta.

A highly-recognized Canadian life sciences leader, Karimah Es Sabar brings 30 years of dynamic global business experience to her role as CEO and Partner of Quark Venture, a Canadian life sciences venture capital firm. She previously held the position of President and CEO of The Centre for Drug Research and Development (CDRD), where she had previously been the Senior Vice-President, Business and Strategic Affairs. She was responsible for ensuring the organization’s long-term sustainability, while leading its business functions and successfully building the many national and international alliances and strategic partnerships which are now contributing significantly to advancing the goals of CDRD. In 2013, Ms. Es Sabar was appointed Founding Chair of the Global Alliance of Leading Drug Discovery and Development Centres, an association of international peer organizations dedicated to translating health research into new medicines.

Prior to joining CDRD, Ms. Es Sabar took on the role of leading BC Biotech in 2005, re-engineering and rebranding the organization to LifeSciences BC. As President, she led the organization to its greatest levels of success as a strong business development organization for the life science industry and the scientific research community. Ms. Es Sabar has also held senior management positions with international multinational companies, most notably as Director International Division, and later Director Marketing and Business Development at Connaught Laboratories Limited [Sanofi Pasteur] based in Toronto. Ms. Es Sabar also served as Vice President and Chief Operating Officer for a Vancouver medical devices company, Medsurge Medical Inc., and was the founder and Managing Director of SAL Healthcare Limited, a leading healthcare organization in Kenya specializing in pharmaceutical marketing, distribution and healthcare consulting services. The company set new standards in the marketing and distribution of biopharmaceutical products in the region.

Ms. Es Sabar currently serves as Chair of the Board of Trustees of the Providence Healthcare Research Institute, and also sits on the Boards of a number of organizations including the Vancouver Prostate Centre; the Prostate Centre’s Translational Research Initiative for Accelerated Discovery and Development (PC-TRiADD); NRC Council, NRC – IRAP Advisory Board, BC Centre for Improved Cardiovascular Health Advisory Board; and is also Past-President of MOSAIC, a multilingual non-profit organization dedicated to addressing issues that affect immigrants and refugees in the course of their settlement and integration into Canadian society. She has also lent her leadership expertise by participating in a number of advisory committees for organizations such as the Natural Sciences and Engineering Research Council of Canada (NSERC); MITACS; the British Columbia Institute of Technology / University of British Columbia Biotechnology Degree Program; The Indus Entrepreneurs (TIE); India Market Advisory Committee, and the British Columbia Asia-Pacific Trade Council. She is also a former board member of LifeSciences British Columbia, the Michael Smith Foundation for Health Research (MSFHR); the Aga Khan National Economic Planning Board of Canada and Aga Khan National Health Boards in Canada and Kenya.

Ms. Es Sabar has been the recipient of a number of awards and recognitions including Canada’s Gold Award for Business Excellence (CABE) while at Sanofi Pasteur; the Women’s Executive Network’s (WXN) “2013 Canada’s Most Powerful Women: Top 100 Award”; the YWCA Women of Distinction Award in 2010 for Industry, Science and Technology; and was included amongst “The Vancouver Power 50” listing of the most influential people in BC by Vancouver Magazine, and “BC’s Top 100 Women of Influence” by the Vancouver Sun. Ms. Es Sabar holds a BSc. Joint Honours degree in Biochemistry/Chemistry from the University of Salford, England, a MSc. degree in Neurochemistry from the Institute of Psychiatry, University of London, England, and an Executive Certificate in Management and Leadership from MIT Sloan School of Management.

• Board of Directors
• Clinical and Research Scientists
• Executive Team

Dr. Goldenberg (CM, OBC, MD, FRCSC, FACS, FCAHS) is a urologic surgeon and clinical scientist with an international reputation for excellence in prostate cancer research and treatment. His current research interests involve the evaluation of artificial intelligence algorithms in reading digitized prostate pathology and MRI to risk stratify active surveillance patients, the identification of targeted radioactive Theranostics ligands (aptamers) for diagnosis and treatment of prostate cancer, prostate cancer supportive care and patient education. He has been recognized for his contributions to health care by being inducted into the Order of British Columbia and the Order of Canada.

• Board of Directors
• Clinical and Research Scientists
• Executive Team

Don Konantz is a father of four, a long time resident of West Vancouver, and a passionate advocate for patients, health care, and prostate cancer research. He holds a Masters of Business Administration from the Ivey School at University of Western Ontario. Don is CEO & Owner of Hops Connect, the leading supplier of hops to Canadian craft breweries. He is also director of the Lake of the Woods Water Sustainability Foundation (since 2007), past President of the Dave Murray National Training Centre, a legacy of the 2010 Olympic Winter Games, Chair of the Collingwood School Foundation and Chair of the Canadian Coalition to Cure Prostate Cancer.​

Don is currently is co-founder and co-president of MdGB Capital, a private company that manages a group assets and operating companies throughout North America.

His prior experience includes: Co-Chair of the British Columbia Premier’s Technology Council; Chief Executive Officer of Zynga; President of Microsoft’s Interactive Entertainment Businesses; President of Worldwide Studios for Electronic Arts; and co-founder/CEO of Distinctive Software Inc. From 1982 through 2014 Don grew multiple businesses with talented teams who were able to reach a ranking of number one in the world in terms of growth rate, market share, product quality and the creation of shareholder value.

In acknowledgement of his role in building these businesses and in recognition of his active development of industry links with the University of British Columbia, Don received the UBC Award as an Honorary Fellow from the Sauder School of Business. He was awarded the highest honor Simon Fraser University can bestow, the Doctor of Laws. He has served on several public and private boards, including the advisory board for USC School of Cinematic Arts, and he continues to actively participate in technology investing and mentorship through MdGB Capital.

Dr. McMaster received a Bachelor and Master of Science from the University of British Columbia, followed by a D.Phil. from the University of Oxford. His research interests are in the areas of molecular immunology, parasitology and transplant immunology and he is co-lead on a multi-million dollar initiative “Biomarkers in Transplantation” with funding from Genome Canada/Genome BC and the Prevention for Organ Failure (PROOF) Center of Excellence Centre.

He is actively involved with national and international granting agencies including the World Health Organization, Canadian Institutes of Health Research where he serves as the as Scientific Officer for the Microbiology and Infectious Diseases Peer Review Grant Committee, and the Michael Smith Foundation for Health Research, having served as Chair of the Research Advisory Council. Dr. McMaster is a Professor in the Department of Medical Genetics and was Head of the Department, 2000-2010. Dr. McMaster also held the positions as Director of the Immunity and Infection Research Centre at Vancouver Coastal Health Research Institute (VCHRI) and Director of Transplant Immunology for British Columbia Transplant.

He is currently the Vice President Research, Vancouver Coastal Health; Executive Director, Vancouver Coastal Health Research Institute; and Associate Dean of Research, Faculty of Medicine, University of British Columbia.

Mr. Parolin has practiced law in Vancouver for over 25 years. He was a founding partner of McClellan, Rubenstein & Parolin, which was formed in 1994, and continued that firm’s real estate and corporate and commercial practice by way of its successor firm, Parolin & Company, until 2013.

He is currently providing legal and advisory services through his law corporation, Parolin Consulting Law Corporation.

Mr. Parolin obtained a Bachelor of Arts degree in 1984, and a Bachelor of Laws degree in 1987, from Queen’s University.
Team

Board of Directors

Mr. Rod Senft is a founder and Managing Director of Tricor and is based in Vancouver. He is involved in all aspects of acquisitions, operations, and the investment, divestiture and management decisions of the firm.

Mr. Senft is Chairman of Advance Engineered Products and Golden Boy Foods, both current Tricor portfolio companies.

Prior to founding Tricor, Mr. Senft was a Principal at Macluan Capital Corporation. He was previously the Chairman and CEO of Hines Nurseries and SunGro Horticulture (companies owned by three of the Principals prior to the formation of Tricor). Until 1993, Mr. Senft was a Partner of Davis & Company, one of Vancouver’s leading law firms. Prior to joining Davis & Company in 1978, Mr. Senft was Secretary and General Counsel for Cargill (Canada) Inc. Before joining Cargill, he practiced law in Winnipeg, Manitoba, with Thompson, Dorfman, Sweatman.

Mr. Senft obtained a Bachelor of Commerce degree and a Bachelor of Law degree from the University of Manitoba.

Team

Board of Directors